Ensuring Safe Access to Mifepristone During the Pandemic and Beyond

The FDA’s REMS program for mifepristone is not justified by the drug’s safety profile and creates access barriers, particularly for low-income and rural patients, that were exacerbated by the COVID-19 pandemic. The authors contend that the REMS requirements may paradoxically push patients toward later surgical abortions that carry greater risk.